The identification of broadly neutralizing monoclonal antibodies against HIV-1 may aid efforts to design a vaccine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wu, X. et al. Science 329, 856–861 (2010).
Zhou, T. et al. Science 329, 811–817 (2010).
Scheid, J.F. et al. J. Immunol. Methods 343, 65–67 (2009).
Kwong, P.D. & Wilson, I.A. Nat. Immunol. 10, 573–578 (2009).
Hammond, P.W. mAbs 2, 157–164 (2010).
Walker, L.M. et al. Science 326, 285–289 (2009).
Pancera, M. et al. J. Virol. 84, 8098–8110 (2010).
Bianchi, E. et al. Proc. Natl. Acad. Sci. USA 107, 10655–10660 (2010).
Bommakanti, G. et al. Proc. Natl. Acad. Sci. USA. 107, 13701–13706 (2010).
Rerks-Ngarm, S. et al. N. Engl. J. Med. 361, 2209–2220 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.G.J. and J.t.M. are employees of Merck & Co.
Rights and permissions
About this article
Cite this article
Joyce, J., ter Meulen, J. Pushing the envelope on HIV-1 neutralization. Nat Biotechnol 28, 929–931 (2010). https://doi.org/10.1038/nbt0910-929
Issue Date:
DOI: https://doi.org/10.1038/nbt0910-929